LOS ANGELES, CA — (Marketwired) — 12/09/14 — (OTCQB: MMRF), through its wholly owned subsidiary, MyMedicalRecords, Inc. (collectively, “MMR”), today announced that on Friday, December 5, 2014, the California Court of Appeal issued an Alternative Writ of Mandate, finding the trial court “erred in granting [Surgery Center Management, LLC–s (“SCM”)] motion for summary adjudication”. The Company believes that the Court of Appeal–s Alternative Order shall soon clear the way for MMR to continue pursuing its claim for as much as $30 million against SCM. It would be the second time the Court of Appeal ruled in favor of MMR in this matter. The full case would then be remanded back to the Los Angeles County Superior Court, where MMR will continue to pursue its claim for breach of contract.
The case stems from a December 9, 2011 Non-Exclusive Settlement and Patent License Agreement. SCM contracted to pay MMR an initial payment of $5 million, payable on December 23, 2011, and additional payments of $5 million per year for five consecutive years, to license certain of MMR–s health IT and patents covering uses of its personal and professional health IT products and services. On January 19, 2012, MyMedicalRecords, Inc. filed a lawsuit in the Superior Court of the State of California for the County of Los Angeles for breach of contract.
In addition to being a practicing entity as a leading provider of Personal Health Records, MyMedicalRecords, Inc. has a health IT patent portfolio that currently consists of 13 issued U.S. patents, 17 pending U.S. applications, and numerous issued patents and pending applications in other countries or regional authorities of commercial interest including Australia, Singapore, New Zealand, Mexico, Japan, Canada, China, Hong Kong, South Korea, Israel and Europe. MMR–s U.S. patents include U.S. Patent Nos. 8,301,466; 8,352,287; 8,352,288; 8,121,855; 8,117,646; 8,117,045; 8,321,240; 8,498,883; 8,626,532, 8,645,161; 8,725,537; 8,768,725 and 8,775,212, as well as additional applications and continuation applications involving inventions pertaining to Personal Health Records, Patient Portals and other Electronic Health Record systems. The most recently issued U.S. patent, U.S. Patent No. 8,775,212, represents MMR–s first Clinical Trials patent and includes 18 claims directed to methods and systems that provide for self-reporting being used to create Electronic Health Records for purposes including Clinical Trials.
Although the Company–s primary focus is as a provider and licensor of health IT products and services, it also has a growing list of patents related to cancer-fighting anti-CD20 monoclonal antibodies under the title, “Antibodies and Methods For Making and Using Them,” issued in the U.S., Mexico, Australia and South Korea, with patents pending in Australia, Brazil, Canada, China, Hong Kong, India, Europe, Japan and Korea. MMR also holds additional patents pertaining to its B-cell idiotype vaccine worldwide.
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user–s account. The Company–s professional offering, , is designed to give physicians– offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId/Specifid vaccine clinical trials for the treatment of B-Cell Non-Hodgkin–s lymphoma. To learn more about MMRGlobal, Inc. visit . View demos and video tutorials of the Company–s products and services at .
All statements in this release that are not strictly historical in nature, whether or not such statement relates directly to Surgery Center Management, LLC, are “forward-looking statements.” Such forward-looking statements are based on MMR–s current assumptions, beliefs and expectations, and involve risks, uncertainties and other factors that may cause MMR–s actual results to be materially different from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words such as “expect,” “plan,” “possibility,” “offer,” “if,” “negotiate,” “when,” “believe,” “will,” “estimate,” “continue,” and similar expressions. Risks, uncertainties, and other factors that could cause or contribute to such differences include, but are not limited to: ongoing and future intellectual property enforcement actions; the ability to successfully litigate or settle claims of patent infringement; MMR–s ability to develop, license and monetize its patent and the additional patents in the portfolio for both MMR–s health IT and biotechnology IP assets; reliance upon the successful operations of its business partners in selling MMR–s products and services, the timing of milestone payments in connection with licensing its IP; MMR–s ability to obtain necessary financing, generate sufficient cash flow, and maintain appropriate indebtedness; and the increasing development of market competition in the area of personal and electronic health records. These factors and others are described in more detail in MMR–s public filings with the Securities and Exchange Commission, including the risks discussed in the “Risk Factors” section in MMR–s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Copies of these reports can be found on MMR–s website () under the heading “Investor Relations.” MMR is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
CONTACT:
Michael Selsman
Public Communications Co.
(310) 922-7033
You must be logged in to post a comment Login